DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20214053

Skin manifestations of autoimmune diseases in the pediatrics

Nawal R. Alyamani, Ridha M. Alsuwayq, Nawaf M. Bahatheq, Zahra A. Alkhatir, Arwa W. Alhawdar, Yousef H. Alharthi, Khalid H. Alqarni, Ebtihal A. Turkistani, Riam S. Alkhamis, Rhonda A. Alkhowaiter, Latifa I. Albrahim, Mohammed A. Safar

Abstract


Autoimmune diseases during childhood are common and are usually observed to affect multiple systems. Among many pediatric autoimmune diseases, several cutaneous manifestations were reported in the literature, and the adequate examination and detection of these manifestations might significantly enhance the chances of establishing an adequate diagnosis of the underlying diseases and conditions because the affected patients usually present with typical symptoms. Establishing a proper diagnosis can enhance the prognosis of the affected patients and might prevent the development of serious complications and other adverse events. Besides, it was also previously indicated that establishing an early diagnosis will furtherly help with deciding the most appropriate interventions, which will also enhance the prognosis of the pediatric population. In this literature review, we have discussed the cutaneous manifestations of several autoimmune diseases that might affect the pediatric population. We have majorly discussed the conditions that are associated with systemic lupus, juvenile idiopathic arthritis, dermatomyositis, juvenile-onset systemic sclerosis and morphea. The cutaneous manifestations of these conditions are hugely variable and usually need careful examination and adequate differential diagnosis to establish the best management modality. Besides, some manifestations might gradually develop which might even make the diagnostic approaches even more difficult. Accordingly, clinicians should provide full and thorough examination and diagnosis of the suspected patients because detecting such cases might significantly enhance the prognosis and lead to adequate treatment. 


Keywords


Autoimmune disease, Pediatric, Systemic lupus erythematosis, Dermatomyositis

Full Text:

PDF

References


De Wit J, Brada RJ, van Veldhuizen J, Dalm VA, Pasmans SG. Skin disorders are prominent features in primary immunodeficiency diseases: a systematic overview of current data. Allergy. 2019;74(3):464-82.

Al‐Herz W, Nanda A. Skin manifestations in primary immunodeficient children. Pediatric Dermatol. 2011;28(5):494-501.

Allenspach E, Torgerson TR. Autoimmunity and primary immunodeficiency disorders. J Clin Immunol. 2016;36(1):57-67.

Pepmueller PH. Undifferentiated Connective Tissue Disease, Mixed Connective Tissue Disease, and Overlap Syndromes in Rheumatology. Missouri Med. 2016;113(2):136-40.

Yun D, Stein SL. Review of the cutaneous manifestations of autoimmune connective tissue diseases in pediatric patients. World. 2015;2.

López-Quintero W, Cleves D, Gomez-Vasco JD. Skin manifestations in pediatric patients with primary immunodeficiency diseases (PIDs) in a tertiary care hospital in Colombia. World Allerg Organiz J. 2021;14(3):100527.

Martini G, Foeldvari I, Russo R. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheumatism. 2006;54(12):3971-8.

Butnor KJ, Khoor A. Collagen Vascular Diseases and Disorders of Connective Tissue. Dail and Hammar’s Pulmonary Pathology: Volume I. Nonneoplastic Lung Disease. 2008:722-59.

Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010;37(1):98-104.

Williams CM, Storm CA, Burns C, Rigby W, Dinulos JG. Ichthyotic-appearing skin changes associated with childhood morphea, systemic sclerosis, and systemic lupus erythematosus/scleroderma overlap. Pediatr Dermatol. 2010;27(2):170-3.

Laxer RM, Zulian F. Localized scleroderma. Curr Opinion Rheumatol. 2006;18(6):606-13.

Abbas L, Joseph A, Kunzler E, Jacobe HT. Morphea: progress to date and the road ahead. Ann Translational Med. 2021;9(5):437.

Chiu YE, Vora S, Kwon EK, Maheshwari M. A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings. Pediatr Dermatol. 2012;29(6):738-48.

Albuquerque JV, Andriolo BN, Vasconcellos MR, Civile VT, Lyddiatt A, Trevisani VF. Interventions for morphea. Cochrane Database Systemat Rev. 2019;7(7):CD005027.

Sapra A, Dix R, Bhandari P, Mohammed A, Ranjit E. A Case of Extensive Debilitating Generalized Morphea. Cureus. 2020;12(5):8117.

Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):432-7.

Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006;24(5):363-73.

Sharma SK, Sharma AL, Mahajan VK. Ophthalmic manifestations in patients with collagen vascular disorders: a hospital-based retrospective observational study. Int Ophthalmol. 2021;41(8):2765-75.

Didona D, Fania L, Didona B, Eming R, Hertl M, Di Zenzo G. Paraneoplastic Dermatoses: A Brief General Review and an Extensive Analysis of Paraneoplastic Pemphigus and Paraneoplastic Dermatomyositis. Int J Mol Sci. 2020;21(6).

Mende M, Borchardt-Lohölter V, Meyer W, Scheper T, Schlumberger W. Autoantibodies in Myositis. How to Achieve a Comprehensive Strategy for Serological Testing. Mediterranean J Rheumatol. 2019;30(3):155-61.

Kasteler JS, Callen JP. Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed. Jama. 1994;272(24):1939-41.

Gowdie PJ, Allen RC, Kornberg AJ, Akikusa JD. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheumat Dis. 2013;16(5):561-7.

Sato JO, Sallum AM, Ferriani VP, et al. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol. 2009;27(6):1031-8.

Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 2010;62(1):63-72.

Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48-49:14-9.

Dickey BZ, Holland KE, Drolet BA. Demographic and clinical characteristics of cutaneous lupus erythematosus at a paediatric dermatology referral centre. Br J Dermatol. 2013;169(2):428-33.

Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391-404.

Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatrics. 2008;152(4):550-6.

Nico MM, Bologna SB, Lourenço SV. The lip in lupus erythematosus. Clin Exp Dermatol. 2014;39(5):563-9.

Lourenço DM, Gomes RC, Aikawa NE, Campos LM, Romiti R, Silva CA. Childhood-onset bullous systemic lupus erythematosus. Lupus. 2014;23(13):1422-5.

Berry T, Walsh E, Berry R, DeSantis E, Smidt AC. Subacute cutaneous lupus erythematosus presenting in childhood: a case report and review of the literature. Pediatr Dermatol. 2014;31(3):368-72.

Dop D, Niculescu CE, Stănescu L, Niculescu D, Stepan A. Atypical debut manifestations in juvenile idiopathic arthritis. Romanian J Morphol Embryol. 2013;54(3):669-73.

Giancane G, Minoia F, Davì S, Bracciolini G, Consolaro A, Ravelli A. IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. Front Pharmacol. 2016;7(467).